Patients with an advanced form of lung cancer lived 56 per cent longer without their disease progressing when radiotherapy was added to the standard of care whole-body therapy, including chemotherapy ...

The Centre for In Vivo Modelling is a newly established research centre within the Division of Cancer Biology at the ICR. Our scientists and clinical researchers use state-of-the-art in vivo models to ...

Experts at The Institute of Cancer Research, London, have hailed findings from a major international trial showing that a personalised cancer vaccine can significantly reduce the risk of melanoma ...

Major new research study identifies potential new ways to treat the most common type of bowel cancer, affecting more than 39,000 people in the UK each year. The study, conducted by an international ...

The division is focused on identifying both the genetic and environmental causes of breast cancer, so we can improve diagnosis, assess prognosis and likely response to treatment more accurately, and ...

Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.

Our researchers play key roles in international research efforts that are transforming how these devastating diseases are treated, as well as pioneering studies of cancer types not studied elsewhere ...

As we enter 2026, scientists at The Institute of Cancer Research, London, share the developments expected this year that could soon change how cancer is treated – from technologies designed to deliver ...

A new AI test can pick out which men with high-risk prostate cancer that has not spread will require life-extending drug abiraterone. Scientists from The Institute of Cancer Research, London, and ...

Image: A scanning electron microscope image of a prostate cancer cell. Credit: Anne Weston, Francis Crick Institute. CC BY-NC 4.0. At The Institute of Cancer Research, London, we often refer to ...

The Institute of Cancer Research, London, works closely with trusts, foundations and charity partners who play an important part in enabling our state-of-the-art research. We recently marked a ...

The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Results released at the ...